Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET.

Somatuline Depot (lanreotide prolonged-release subcutaneous) - Ipsen, Teijin

octreotide subcutaneous depot (CAM2029) - Camurus

Sandostatin LAR Depot (octreotide acetate) - Novartis

http://www.ncbi.nlm.nih.gov/pubmed/38229199

Agneta Svedberg; Daniel Halperin; Diego Ferone; Fredrik Tiberg; Hanna Liedman; Jaume Capdevila; Jennifer Ang Chan; Josh Mailman; Lisa Hellström; Simron Singh; Wouter W de Herder

Jan 17, 2024